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Background: Neostigmine augments clindamycin-induced neuromuscular block and antagonizes rocuronium-
induced neuromuscular block; however, it remains unclear whether neostigmine enhances the neuromuscular 
blocking (NMB) that is caused by combinations of rocuronium and clindamycin. The intent of this study was to 
determine whether neostigmine potentiates the muscle relaxation that is induced by combinations of rocuronium 
and clindamycin and to estimate whether both clindamycin and rocuronium have synergistic actions on NMB.
Methods: Forty-one left phrenic nerve-hemidiaphragms (from male Sprague-Dawley rats, 150-250 g) were mounted 
in Krebs solution. Three consecutive single twitches (ST, 0.1 Hz) and one tetanic tension (50 Hz for 1.9 s) were 
obtained for each increase in concentration of rocuronium or clindamycin. The concentrations of rocuronium were 
cumulatively increased until an 80% to 90% reduction in ST was attained in the Krebs solutions pre-treated with 0 
(n = 5), 0.1 (n = 1), 0.25 (n = 1), 0.5 (n = 4), or 1.0 (n = 1) mM clindamycin or with 0 (n = 4), 0.1 (n = 1), 0.5 (n = 5), 1.0 
(n = 5), or 2.0 (n = 4) mM clindamycin in combination with 250 nM neostigmine, and so were the concentrations of 
clindamycin in the Krebs solutions pre-treated with 0 (n = 6) or 250 nM (n = 6) neostigmine.
Results: Clindamycin increased the potency of rocuronium for ST and tetanic fade, irrespective of the presence of 
neostigmine. Neostigmine shifted the concentration-response curve of rocuronium to the right in the presence or 
absence of clindamycin. The interaction between rocuronium and clindamycin was synergistic when clindamycin 
concentrations were in excess of 0.5 mM, irrespective of the presence of neostigmine.
Conclusions: Neostigmine may partially antagonize the neuromuscular block that is induced by a combination 
of clindamycin and rocuronium. Clinicians are advised to be aware that clindamycin synergistically increases the 
degree of rocuronium-induced neuromuscular block, even when neostigmine is present. (Korean J Anesthesiol 2011; 
61: 320-326)
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Introduction
Because many antibiotics are administered 60 minutes 
before surgical incision to prevent surgical site infection 
[1], perioperative antimicrobials are typically administered 
before anaesthesia. Anaesthesiologists are often responsible 
for the administration of antibiotics in the preoperative and 
intraoperative periods; however, they may be unfamiliar 
that the administration of antibiotics is associated with the 
potentiation of neuromuscular blocking (NMB) agents [2].
Most antibiotics have been reported to cause neuromuscular 
block in the absence of NMB drugs [3]. Therefore, the use of 
antibiotics can prolong the duration of mechanical ventilation 
[4,5]. Because some antibiotics can not only enhance NMB 
drug-induced muscle relaxation, but also complicate the 
antagonism of the neuromuscular block, control of ventilation is 
necessary until there is spontaneous recovery of the neuromu-
scular block [6].
Clindamycin is a 7-chloro-7-deoxy derivative of lincomycin. 
Clindamycin has typically been used to treat infections that are 
caused by anaerobic and aerobic bacteria other than enterococci 
[1]. In addition to having antibacterial effects, clindamycin 
produces an open ion channel block on the end-plate [7,8] and 
decreases acetylcholine release at the motor nerve terminal 
[9], thus, prolonging or enhancing neuromuscular block that is 
caused by nondepolarizing NMB drugs [10-14]. 
While neostigmine antagonizes nondepolarizing NMB drug-
induced neuromuscular block, it augments or incompletely 
antago  nizes the NMB that is induced by combinations of some 
antibiotics and NMB drugs [11,15,16]. It has been demon-
strated that neostigmine augments clindamycin-induced 
neuromuscular block [17]; however, it remains unclear whether 
neostigmine enhances the neuromuscular block that is caused 
by a combination of rocuronium and clindamycin.
Becker and Miller [11] have shown that the combination of 
clindamycin and d-tubocurarine or pancuronium synergisti-
cally depresses twitch tension. However, there are no reports 
investigating the effect of clindamycin on rocuronium-induced 
muscle relaxation or the interaction between clindamycin and 
rocuronium on neuromuscular block. The Loewe additivity 
model [18] has been established as the universal reference 
model for classifying drug interactions [19]. When the 
interaction index as per the Berenbaum method [20] is equal to, 
less than or greater than unity, the combination dose is labelled 
as additive, synergistic or antagonistic, respectively.
The intent of this study was to determine whether neostig-
mine potentiates the muscle relaxation that is induced by 
combinations of rocuronium and clindamycin and to estimate 
whether both clindamycin and rocuronium have synergistic 
actions on neuromuscular block.
Materials and Methods
The Institutional Animal Care and Use Committee approved 
the experimental protocol. All experimental courses followed 
the Guide for the Care and Use of Laboratory Animals provided 
by the National Academy of Sciences. Forty-one male Sprague-
Dawley rats (150-250 g in weight) were anesthetized by a 
perivertebral injection of propofol (50 mg/kg) at the lumbar 
level and then killed. The phrenic nerve and diaphragm were 
excised together and the left diaphragm with the middle 
diaphragmatic ligament was separated from the rest of the 
diaphragm. Left phrenic nerve-hemidiaphragm preparations 
were mounted in a 20-ml organ bath that had been filled with 
Krebs solution (118 mM NaCl, 5 mM KCl, 2.5 mM CaCl2, 30 mM 
NaHCO3, 1 mM KH2PO4, 1 mM MgCl2 and 11 mM glucose). The 
bath solution was maintained at 32
oC and was continuously 
aerated with a gas mixture of 95% oxygen and 5% carbon 
dioxide. The pH of the bath solution was maintained at 7.38 to 
7.42. Spent Krebs solution was exchanged with fresh solution 
10 min after the preparation was mounted. The preparation was 
attached to a force transducer (Model 1030, UFI, Morro Bay, 
CA, USA) with a stainless steel wire and allowed to stabilize 
for 20 min in the bath. The phrenic nerve, connected to an 
electrode, was stimulated with supramaximal square wave 
impulses of 0.2 ms in duration using a stimulator (Model 
ML112, ADInstruments Pty Ltd, Bella Vista, NSW, Australia).
The diaphragm muscle was stretched until the maximum 
output tension was recorded after stimulation, followed by 
another 10 min for stabilization before the experiment began. 
Three consecutive single twitch tensions at 0.1 Hz and a 1.9-s 
tetanic tension of 50 Hz were obtained at each concentration, 
which were then digitized and stored on a Power Macintosh 
7100 (Apple Computer Corp, Cupertino, CA, USA) using data 
acquisition software (MacLab, ADInstruments Pty Ltd, Bella 
Vista, NSW, Australia).
After baseline tensions were measured, the concentrations 
of rocuronium were cumulatively increased until an 80% to 90% 
reduction in a single twitch (ST) was reached in Krebs solution 
pre-treated with 0 (n = 5), 0.1 (n = 1), 0.25 (n = 1), 0.5 (n = 4) 
or 1.0 (n = 1) mM of clindamycin phosphate alone or in Krebs 
solution pre-treated with 0 (n = 4), 0.1 (n = 1), 0.5 (n = 5), 1.0 
(n = 5), or 2.0 (n = 4) mM of clindamycin in combination with 
250 nM neostigmine. For synergy testing, the concentrations of 
clindamycin were cumulatively increased until an 80% to 90% 
reduction in ST was reached in Krebs solution pre-treated with 
0 (n = 5) or 250 nM (n = 5) of neostigmine.
A period of at least 20 min was allowed to pass to establish 
a pseudo-steady state condition of each drug concentration 
between bath and the tissue preparation. Tension measure-
ments were made during the pseudo-steady state and in 322 www.ekja.org
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the drug-free solution after completion of each experiment. 
Data were analyzed only if the single-twitch tension returned 
to greater than 90% of the baseline recording in a drug-free 
solution. Single-twitch tension was calculated based on the 
average of three consecutive single-tension measurements. The 
effective concentrations (EC) of rocuronium or clindamycin 
for ST (percent reduction of control) and TF (tetanic fade: 
percent increase of TF) were determined by the probit model 
[17] and the concentration-response curves of rocuronium and 
clindamycin were obtained for each pre-treatment.
To evaluate the ability of neostigmine to potentiate the NMB 
action of clindamycin in combination with rocuronium, the 
potency ratios, which were equated with the EC50 of rocuronium 
with clindamycin (0.5 and 1.0 mM) to the EC50 of rocuronium in 
the absence or in the presence of neostigmine, were calculated 
and compared to one another.
The interaction between rocuronium and clindamycin was 
determined using an interaction index [20] from the following 
equation:
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where cR and cCl are the concentrations of rocuronium and 
clindamycin, respectively, both of which yield an effect, E while 
CR and CCl are the concentrations of each drug that produce the 
same effect of E when given alone.
The EC50’s of rocuronium given with clindamycin or those 
of rocuronium given with clindamycin in combination with 
neostigmine were compared using a Student’s t-test with a 
Bonferroni’s correction of the significance level. The EC50’s of 
clindamycin in the absence and presence of neostigmine were 
compared to one another using a Student’s t-test, and the EC50’s 
of rocuronium with 0.5 mM clindamycin in the absence and 
presence of neostigmine were also compared using a Student’s 
t-test. Differences were considered significant when P < 0.05.
Results
Clindamycin shifted the concentration-response curves of 
rocuronium to the left (Fig. 1 and 2) as well as increased the 
potency of rocuronium for both a ST and TF, irrespective of the 
presence of neostigmine. Clindamycin at 1.0 mM moved the 
concentration-response curve of rocuronium in the presence of 
neostigmine to that of rocuronium alone (Fig. 2).
To determine whether neostigmine antagonizes the 
neuromuscular block that is caused by combinations of 
clindamycin and rocuronium, the concentration-response 
relationships of rocuronium in combination with clindamycin 
or neostigmine were performed. Neostigmine at 250 nM 
shifted the concentration-response curve of rocuronium to the 
right (Fig. 2), irrespective of the presence of clindamycin, and 
increased the EC50 of rocuronium with the same clindamycin 
concentration by approximately two-fold (Table 1). It was 
demonstrated that neostigmine partially antagonized the 
neuromuscular block that was induced by both clindamycin 
and rocuronium.
We examined the ability of neostigmine to potentiate the 
NMB action of clindamycin in combination with rocuronium 
by calculating the potency ratios of rocuronium. The potency 
ratios of rocuronium with neostigmine were higher than or 
similar to those observed in the absence of neostigmine (Table 1). 
Neostigmine failed to enhance the neuromuscular block which 
Fig. 1. Based on the cumulative concentration-effect curves for rocuronium on a ST at 0.1 Hz (A) and TF at 50 Hz for 1.9 seconds (B), 
clindamycin shifted curves to the left; thus, clindamycin augments the potency of rocuronium. Twelve preparations were studied. Rocuronium 
concentrations are presented as means ± SD and where a single experiment was performed (n = 1, no SD). CM: clindamycin. *Indicates P < 
0.0009, EC50 of rocuronium in 0.5 mM clindamycin compared to no clindamycin.323 www.ekja.org
Korean J Anesthesiol Kim, et al.
was induced by both clindamycin and rocuronium.
Neostigmine shifted the concentration-response curves of 
clindamycin to the left and enhanced the effect of clindamycin 
(Fig. 3).
The interaction indices were less than 0.7 for a ST and TF 
with concentrations of clindamycin in excess of 0.5 mM without 
neostigmine (Fig. 4). In the presence of neostigmine, the 
interaction indices were less than 0.7 for a ST and less than 0.9 
for TF with concentrations higher than 1.0 mM of clindamycin 
(Fig. 5). Because the interaction indices were less than one, the 
two drugs interacted synergistically. In view of the influence 
of neostigmine on the interaction index, neostigmine failed to 
boost the interaction of rocuronium and clindamycin.
Discussion
It was demonstrated that neostigmine fails to augment the 
degree of neuromuscular block caused by both rocuronium 
and clindamycin. On the contrary, neostigmine partially 
antagonizes the effect of rocuronium and clindamycin combi-
nations, whereas neostigmine reduces the rocuronium potency 
with both clindamycin and neostigmine less than with neostig-
Fig. 2. Based on the cumulative concentration-effect curves for rocuronium on a ST at 0.1 Hz (A) and TF at 50 Hz for 1.9 seconds (B), 
clindamycin shifted curves to the left; hence, clindamycin augments the potency of rocuronium in the presence of neostigmine. Clindamycin 
at 1.0 mM shifted the concentration-response curve of rocuronium in the presence of neostigmine to the rocuronium alone curve. Rocuronium 
concentrations are presented as means ± SD except where a single experiment was performed (n = 1, no SD). CM: clindamycin, R alone: 
rocuronium in the absence of both clindamycin and neostigmine. *Indicates P < 0.05, EC50 of rocuronium with 0.5 mM clindamycin and 
†Indicates P < 0.005, EC50 of rocuronium with 1.0 mM clindamycin compared to no clindamycin.
Table 1. EC50 (μM) and Potency Ratios (PR = EC50,R+CM/EC50,R) for Rocuronium with Different Pre-Treatments
Pretreatments n
ST TF
EC50 PR EC50 PR
R alone
R in 0.5 mM CM
R in 1.0 mM CM
R in NS
R in 0.5 mM CM + NS
R in 1.0 mM CM + NS
5
4
1
4
5
5
15.5 ± 0.4
9.2 ± 0.9*
8.6
28.4 ± 5.3
21.8 ± 3.7
15.5 ± 2.8
†
0.6 ± 0.1
‡
0.6
0.8 ± 0.1
0.5 ± 0.1
6.1 ± 9
3.5 ± 0.7*
3.3 
10.5 ± 0.8
8.2 ± 2.1
5.7 ± 1.2
†
0.6 ± 0.1
§
0.5
0.8 ± 0.2
0.5 ± 0.1
EC50: effective concentrations of 50% maximal effect of rocuronium, EC50,R+CM: EC50 of rocuronium  with clindamycin with or without 
neostigmine, EC50,R: EC50 of rocuronium alone or with neostigmine, CM: clindamycin, NS: 250 nM neostigmine, R: rocuronium, ST: single 
twitch, TF: tetanic fade. *Indicates P < 0.0009, versus rocuronium alone, 
†indicates P < 0.005, versus rocuronium with neostigmine, 
‡indicates 
P = 0.02, versus PR in 0.5 mM CM + NS, 
§indicates P = 0.05, versus PR in 0.5 mM CM + NS.324 www.ekja.org
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mine alone. Therefore, neostigmine may be used to reverse 
the muscle relaxation that is induced by combinations of 
rocuronium and clindamycin.
A recent clinical report demonstrated that neostigmine 
fails to reverse both rocuronium and oral neomycin-induced 
neuromuscular block [16]. Edrophonium, neostigmine and 
pyridostigmine at sub-clinical dosages were observed to weakly 
antagonize the NMB of polymyxin B; however, at anti-curare 
dosages, they were observed to enhance the NMB [21]. Van 
Nyhuis et al. [15] observed that neostigmine augments the 
neuromuscular block caused by polymyxin B alone as well 
as in combination with pancuronium or d-tubocurarine. The 
antagonism by neostigmine and calcium may be incomplete 
at reversing the clindamycin-induced block [11] even though 
neostigmine augments clindamycin-induced neuromuscular 
block [17]. However, the results of this study indicate that 
neostigmine shifts the concentration-response curves of 
rocuronium to the right in the presence of clindamycin, which 
is a phenomenon that has not been observed for polymyxin B. 
The reason for this discrepancy in the response to neostigmine 
between clindamycin and polymyxin B is not known; however, 
variations in the study designs, such as the use of different 
NMB drugs, animal species, concentrations of neostigmine and 
muscles studied, in addition to possible differences between 
the two drugs themselves, may be potential causes.
The results of this study indicate that in rat left phrenic 
nerve-hemidiaphragm preparations, clindamycin enhances 
rocuronium-induced neuromuscular block, whether or not 
neostigmine is present. We found that increasing the con-
centration of clindamycin went together with increasing 
rocuronium potency and the investigated concentrations of 
clindamycin produced little muscle relaxation.
Clindamycin causes muscle relaxation alone [17,22], 
enhances the activities of d-tubocurarine and pancuronium 
[11] in addition to prolonging the rapacuronium-induced 
neuromuscular block [14]. Consistent with what has been 
Fig. 3. Cumulative concentration-response curves of clindamycin in 
the absence (n = 6) or presence (n = 6) of 250 nM neostigmine on ST 
(0.1 Hz) and TF (50 Hz) for 1.9 seconds. The indicated concentrations 
of clindamycin represent the means ± SD of five preparations. CM, 
NS, ST or TF represents clindamycin, neostigmine, single twitch 
or tetanic fade, respectively. *Indicates P < 0.000009 for TF, and 
†indicates P < 0.00004 for a ST when compared to the effect of 
clindamycin alone.
Fig. 4. Interaction indices as % inhibition of a ST are less than 0.9 with clindamycin concentrations of 0.25, 0.5 and 1.0 mM, indicating a 
synergistic interaction. The interaction indices with a clindamycin concentration of 0.1 mM lie between 0.9 and 1.1, indicating an additive 
interaction (A). The interaction indices in % increase of TF are less than 0.9 with clindamycin concentrations of 0.5 and 1.0 mM; the interaction 
is synergistic. The interaction indices at a clindamycin concentration of 0.25 mM lie between 0.9 and 1.1; the interaction is additive (B). Data are 
expressed as means ± SD except when n = 1. CM: clindamycin.325 www.ekja.org
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observed for other muscle relaxants, the results of this study 
indicate that clindamycin augments rocuronium-induced 
neuromuscular block.
Various explanations for the mechanism of clindamycin-
induced neuromuscular block are diverse. Some researchers 
have reported that clindamycin reduces end-plate current 
amplitude via an exclusive decrease in the quantal content of 
the end-plate current [7]. Some researchers have found that 
clindamycin affects end-plate current (or potential) decay, 
amplitude and quantal content; they concluded that the NMB 
effects of clindamycin involve both pre- and post-junctional 
sites [8,9]. Others have found that clindamycin post-junctionally 
produces a neuromuscular block by interacting with the open 
state of the acetylcholine-receptor (AChR) ion-channel complex 
[8]. Based on the findings of this study that augmentation of the 
neuromuscular block by clindamycin occurred in the presence 
of neostigmine, clindamycin probably blocks the open ion 
channels in the end-plate. 
Chou and Hayball [23] have proposed that an interaction 
index between 0.9 and 1.1 designates an additive interaction. 
The interaction indices that were observed in this study indicate 
that clindamycin and rocuronium were synergistic in the 
depression of neuromuscular transmission according to Chou 
and Hayball’s criteria.
Although it remains to be tested, several phenomena may 
account for the synergy of the two drugs. For example, clin-
damycin decreases the end-plate sensitivity to acetylcholine 
[24], increases acetylcholine receptor sensitivity to rocuronium, 
exerts a direct depressant action on muscle contractility [25], or 
acts with local anaesthetic activity [26]. Therefore, rocuronium 
may facilitate the channel blocking of clindamycin, or it may be 
that both rocuronium and clindamycin collaborate to decrease 
presynaptic acetylcholine mobilization, enhance AChR 
desensitization or influence the rates of binding to or unbinding 
from the AChR or the open channel [27,28]. In addition, it has 
been claimed that mutually nonexclusive drugs contain an 
element of intrinsic synergism, which may contribute to the 
overall synergism [29]. Because they act on the different sites in 
AChR ion channel complex, rocuronium and clindamycin may 
be mutually nonexclusive and offer some degree of intrinsic 
synergism. 
Neostigmine slightly reduces the degree of synergistic 
interaction between clindamycin and rocuronium. Some 
complicated interactions between the three drugs may 
occur during their presence in the neuromuscular junction. 
First, acetylcholine release is decreased by clindamycin and 
rocuronium. Second, open-channel blocking by clindamycin 
and AchR occlusion by rocuronium could occur postsynapti-
cally. Finally, it is possible that a small amount of released 
acetylcholine limits the increase by neostigmine in the amount 
of acetylcholine in neuromuscular junction and prohibits 
opening enough channels to enhance ion-channel block of 
clindamycin. Thus, it may be that neostigmine fails to increase 
the degree of synergistic interaction between clindamycin and 
rocuronium.
Clindamycin potentiates rocuronium action, but only 
clinically produces a muscle relaxation by itself in the setting 
of a clindamycin overdose (2,400 mg i.v. bolus) [22]. A dose 
of 900 mg of clindamycin administered intravenously every 
eight hours is recommended when treating serious infections, 
Fig. 5. The interaction indices as % inhibition of a ST are less than 0.9 at clindamycin concentrations of 0.5, 1.0, 2.0 and 5.0 mM, indicating 
the interaction between rocuronium and clindamycin is synergistic with a neostigmine concentration of 250 nM (A). The interaction indices 
as % increase of TF are less than 0.9 with clindamycin concentrations of 1.0 and 2.0 mM, indicating that the interaction with a neostigmine 
concentration of 250 nM is synergistic. The interaction indices at a clindamycin concentration of 0.5 mM lie between 0.7 and 1.1, indicating an 
additive interaction (B). Values are means ± SD except when n = 1. CM: clindamycin.326 www.ekja.org
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and this dosage results in a serum concentration of 10 to 40 
μg/ml (approximately 0.03 to 0.1 mM) [30]. The clindamycin 
concentrations that were studied in this investigation are 
approximately five to twenty times the aforementioned clinical 
dose and do not cause neuromuscular block. 
To diminish the number of rats used, four single (n = 1) 
experiments were conducted. Data from each single experiment 
were treated as a group by correcting the significance level 
with Bonferroni correction. We believe these single point data 
should be useful in interpreting the findings that were observed 
in this study.
It was shown that neostigmine fails to potentiate the 
neuromuscular block which is caused by both clindamycin and 
rocuronium and can partially antagonize the neuromuscular 
block induced by both rocuronium and clindamycin. Clinicians 
should be aware that clindamycin synergistically increases the 
degree of rocuronium-induced muscle relaxation, even in the 
presence of neostigmine.
References 
1. Kujath P, Bouchard R, Scheele J, Esnaashari H. Current periopera-
tive antibiotic prophylaxis. Chirurg 2006; 77: 490, 492-8. 
2. Cheng EY, Nimphius N, Hennen CR. Antibiotic therapy and the 
anesthesiologist. J Clin Anesth 1995; 7: 425-39. 
3. Naguib M, Lien CA. Pharmacology of muscle relaxants and their 
antagonists. In: Miller's Anesthesia. 6th ed. Edited by RD Miller: 
Philadelphia, Elsevier Churchill Livingstone. 2005, pp 481-572. 
4. Vieira JM Jr, Castro I, Curvello-Neto A, Demarzo S, Caruso P, Pastore 
L Jr, et al. Effect of acute kidney injury on weaning from mechanical 
ventilation in critically ill patients. Crit Care Med 2007; 35: 184-91. 
5. Howard RS, Tan SV, Z'Graggen WJ. Weakness on the intensive care 
unit. Pract Neurol 2008; 8: 280-95. 
6. Bruckner J, Thomas KC Jr, Bikhazi GB, Foldes FF. Neuromuscular 
drug interactions of clinical importance. Anesth Analg 1980; 59: 
678-82. 
7. Prior C, Fiekers JF, Henderson F, Dempster J, Marshall IG, Parsons 
RL. End-plate ion channel block produced by lincosamide anti-
biotics and their chemical analogs. J Pharmacol Exp Ther 1990; 255: 
1170-6. 
8. Fiekers JF. Sites and mechanisms of antibiotic-induced neuromu-
scular block: A pharmacological analysis using quantal content, 
voltage clamped end-plate currents and single channel analysis. 
Acta Physiol Pharmacol Ther Latinoam 1999; 49: 242-50. 
9. Singh YN, Marshall IG, Harvey AL. Pre- and postjunctional blocking 
effects of aminoglycoside, polymyxin, tetracycline and lincosamide 
antibiotics. Br J Anaesth 1982; 54: 1295-306. 
10. Fogdall RP, Miller RD. Prolongation of a pancuronium-induced 
neuromuscular blockade by clindamycin. Anesthesiology 1974; 41: 
407-8. 
11. Becker LD, Miller RD. Clindamycin enhances a nondepolarizing 
neuromuscular blockade. Anesthesiology 1976; 45: 84-7. 
12. Jedeikin R, Dolgunski E, Kaplan R, Hoffman S. Prolongation of 
neuromuscular blocking effect of vecuronium by antibiotics. 
Anaesthesia 1987; 42: 858-60. 
13. de Gouw NE, Crul JF, Vandermeersch E, Mulier JP, van Egmond J, 
Van Aken H. Interaction of antibiotics on pipecuronium-induced 
neuromuscular blockade. J Clin Anesth 1993; 5: 212-5. 
14. Sloan PA, Rasul M. Prolongation of rapacuronium neuromuscular 
blockade by clindamycin and magnesium. Anesth Analg 2002; 94: 
123-4. 
15. Van Nyhuis LS, Miller RD, Fogdall RP. The interaction between 
d-tubocurarine, pancuronium, polymyxin B, and neostigmine on 
neuromuscular function. Anesth Analg 1976; 55: 224-8. 
16. Hasfurther DL, Bailey PL. Failure of neuromuscular blockade 
reversal after rocuronium in a patient who received oral neomycin. 
Can J Anaesth 1996; 43: 617-20. 
17. Lee SI, Lee JH, Lee SC, Lee JM, Lee JH. Calcium and neostigmine 
antagonize gentamicin, but augment clindamycin-induced tetanic 
fade in rat phrenic nerve-hemidiaphragm preparations. J Anesth 
2008; 22: 385-90. 
18. Loewe S. The problem of synergism and antagonism of combined 
drugs. Arzneimittelforschung 1953; 3: 285-90. 
19. Greco WR, Bravo G, Parsons JC. The search for synergy: A critical 
review from a response surface perspective. Pharmacol Rev 1995; 
47: 331-85. 
20. Berenbaum MC. What is synergy? Pharmacol Rev 1989; 41: 93-141. 
21. Lee C, Chen D, Nagel EL. Neuromuscular block by antibiotics: 
Polymyxin B. Anesth Analg 1977; 56: 373-7. 
22. al Ahdal O, Bevan DR. Clindamycin-induced neuromuscular 
blockade. Can J Anaesth 1995; 42: 614-7. 
23. Chou TC, Hayball M. CalcuSyn for windows: Multiple-drug dose-
effect analyzer and manual. Biosoft, Cambridge Place, Cambridge, 
United Kingdom. 1996. 
24. Rubbo JT, Gergis SD, Sokoll MD. Comparative neuromuscular 
effects of lincomycin and clindamycin. Anesth Analg 1977; 56: 329-
32. 
25. Fiekers JF, Marshall IG, Parsons RL. Clindamycin and lincomycin 
alter miniature endplate current decay. Nature 1979; 281: 680-2. 
26. Jonsson M, Gurley D, Dabrowski M, Larsson O, Johnson EC, Eriksson 
LI. Distinct pharmacologic properties of neuromuscular bloc  king 
agents on human neuronal nicotinic acetylcholine receptors: A 
possible explanation for the train-of-four fade. Anesthesiology 2006; 
105: 521-33. 
27. Skok VI. Channel-blocking mechanism ensures specific blockade 
of synaptic transmission. Neuroscience 1986; 17: 1-9. 
28. Peper K, Bradley RJ, Dreyer F. The acetylcholine receptor at the 
neuromuscular junction. Physiol Rev 1982; 62: 1271-340. 
29. Chou TC. Theoretical basis, experimental design, and computerized 
simulation of synergism and antagonism in drug combination 
studies. Pharmacol Rev 2006; 58: 621-81. 
30. Zambrano D. Clindamycin in the treatment of obstetric and gyne-
cologic infections: A review. Clin Ther 1991; 13: 58-80. 